These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

327 related items for PubMed ID: 1919629

  • 21. A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer.
    Conte PF, Bruzzone M, Chiara S, Sertoli MR, Daga MG, Rubagotti A, Conio A, Ruvolo M, Rosso R, Santi L.
    J Clin Oncol; 1986 Jun; 4(6):965-71. PubMed ID: 3519886
    [Abstract] [Full Text] [Related]

  • 22. [Intraperitoneal high dose chemotherapy as consolidation treatment for advanced ovarian carcinoma: a pilot study].
    Gladieff L, Chatelut E, Gaspard MH, Skaf R, de Forni M, Mihura J, Canal P, Bugat R.
    Bull Cancer; 1999 Jun; 86(7-8):673-7. PubMed ID: 10477384
    [Abstract] [Full Text] [Related]

  • 23. Randomized study comparing carboplatin/cyclophosphamide and cisplatin/cyclophosphamide as first-line treatment in patients with stage III/IV epithelial ovarian cancer and small volume disease. German Ovarian Cancer Study Group (GOCA).
    Meerpohl HG, Sauerbrei W, Kühnle H, Schumacher M, Pfleiderer A.
    Gynecol Oncol; 1997 Jul; 66(1):75-84. PubMed ID: 9234925
    [Abstract] [Full Text] [Related]

  • 24. Results of a Southwest Oncology Group phase III trial of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide in advanced ovarian cancer.
    Hannigan EV, Green S, Alberts DS, O'Toole R, Surwit E.
    Oncology; 1993 Nov; 50 Suppl 2():2-9. PubMed ID: 8233297
    [Abstract] [Full Text] [Related]

  • 25. Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische Onkologie.
    du Bois A, Lück HJ, Meier W, Möbus V, Costa S, Richter B, Bauknecht T, Warm M, Schroeder W, Olbricht S, Nitz U, Jackisch C.
    Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-28-S11-33. PubMed ID: 9314296
    [Abstract] [Full Text] [Related]

  • 26. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer.
    Alberts DS, Green S, Hannigan EV, O'Toole R, Stock-Novack D, Anderson P, Surwit EA, Malvlya VK, Nahhas WA, Jolles CJ.
    J Clin Oncol; 1992 May; 10(5):706-17. PubMed ID: 1569443
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Paclitaxel by 24- or 1-hour infusion n combination with carboplatin in advanced non-small cell lung cancer: the Fox Chase Cancer Center experience.
    Langer CJ, Leighton JC, Comis RL, O'Dwyer PJ, McAleer CA, Bonjo CA, Engstrom PF, Litwin S, Johnson S, Ozols RF.
    Semin Oncol; 1995 Aug; 22(4 Suppl 9):18-29. PubMed ID: 7544025
    [Abstract] [Full Text] [Related]

  • 31. Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel.
    Hoskins P, Vergote I, Cervantes A, Tu D, Stuart G, Zola P, Poveda A, Provencher D, Katsaros D, Ojeda B, Ghatage P, Grimshaw R, Casado A, Elit L, Mendiola C, Sugimoto A, D'Hondt V, Oza A, Germa JR, Roy M, Brotto L, Chen D, Eisenhauer EA.
    J Natl Cancer Inst; 2010 Oct 20; 102(20):1547-56. PubMed ID: 20937992
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Cisplatin-MECY (methotrexate-leucovorin rescue plus cyclophosphamide) versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III-IV ovarian adenocarcinoma.
    Barlow JJ, Lele SB.
    Cancer Treat Rep; 1984 Dec 20; 68(12):1433-8. PubMed ID: 6439408
    [Abstract] [Full Text] [Related]

  • 34. Paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer.
    Langer CJ, Leighton J, McAleer C, Comis R, O'Dwyer P, Ozols R.
    Semin Oncol; 1995 Jun 20; 22(3 Suppl 6):64-9. PubMed ID: 7541156
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. A pilot study of paclitaxel and carboplatin for recurrent ovarian cancer.
    Adachi S, Ogasawara T, Ito K, Koyama M, Nagano T, Suzuki A, Yamada T, Nakata Y, Ozawa M.
    Oncol Rep; 2001 Jun 20; 8(2):285-8. PubMed ID: 11182041
    [Abstract] [Full Text] [Related]

  • 37. Carboplatin and short-infusion paclitaxel in high-risk and advanced-stage ovarian carcinoma.
    Coleman RL, Bagnell KG, Townley PM.
    Cancer J Sci Am; 1997 Jun 20; 3(4):246-53. PubMed ID: 9263631
    [Abstract] [Full Text] [Related]

  • 38. Combination therapy with carboplatin/cisplatin/ifosfamide/etoposide in ovarian cancer.
    Lund B, Hansen OP, Hansen HH, Hansen M.
    Semin Oncol; 1992 Feb 20; 19(1 Suppl 1):26-9. PubMed ID: 1411618
    [Abstract] [Full Text] [Related]

  • 39. Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer: a phase I trial.
    Meerpohl HG, du Bois A, Luck HJ, Kühnle H, Möbus V, Kreienberg R, Bauknecht T, Köchli O, Bochtler H, Diergarten K.
    Semin Oncol; 1997 Feb 20; 24(1 Suppl 2):S2-17-S2-22. PubMed ID: 9045330
    [Abstract] [Full Text] [Related]

  • 40. Intraperitoneal administration of cisplatin and 5-fluorouracil in residual ovarian cancer: a Phase II Gynecologic Oncology Group trial.
    Braly PS, Berek JS, Blessing JA, Homesley HD, Averette H.
    Gynecol Oncol; 1995 Feb 20; 56(2):164-8. PubMed ID: 7896179
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.